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Summary
The hormone leptin plays a crucial role inmaintenance of bodyweight and glucose homeostasis. This occurs through central
and peripheral pathways, including regulation of insulin secretion by pancreatic b cells. To study this further in mice, we dis-
rupted the signaling domain of the leptin receptor gene in b cells and hypothalamus. These mice develop obesity, fasting
hyperinsulinemia, impaired glucose-stimulated insulin release, and glucose intolerance, similar to leptin receptor null
mice. However, whereas complete loss of leptin function causes increased food intake, this tissue-specific attenuation
of leptin signaling does not alter food intake or satiety responses to leptin. Moreover, unlike other obese models, these
mice have reduced fasting blood glucose. These results indicate that leptin regulation of glucose homeostasis extends
beyond insulin sensitivity to influence b cell function, independent of pathways controlling food intake. These data suggest
that defects in this adipoinsular axis could contribute to diabetes associated with obesity.Introduction
In many countries, the prevalence of diabetes is increasing at an
alarming rate. The highest rates are observed among popula-
tions that have undergone changes in diet, physical activity,
and life span that are associated with modernization and adop-
tion of a ‘‘Western’’ lifestyle. The obesity that often develops
with this lifestyle is clearly a risk factor for diabetes; z80% of
subjects with diabetes are obese. The adipocyte-derived hor-
mone leptin, which is present in the circulation at levels propor-
tional to the mass of body fat stores (Maffei et al., 1995), may be
a key factor linking diabetes and obesity. The effect of leptin as
a satiety factor that can limit stores of lipid is well documented;
however, leptin has other profound effects on metabolism
(Ahima and Flier, 2000; Friedman and Halaas, 1998; Myers,
2004). Mice that are deficient in either leptin (ob/ob mice) or sig-
naling via the leptin receptor (db/db mice) develop both obesity
and diabetes. The severity of both conditions can be dramati-
cally attenuated by leptin therapy (Pelleymounter et al., 1995)
or restoration of leptin signaling (Kowalski et al., 2001).
Traditionally, the insulin resistance and hyperglycemia that
develop in ob/ob and db/db mice have been attributed as a sec-
ondary consequence of obesity. However, several observations
challenge this concept and suggest that the diabetes and obe-
sity phenotypes can be segregated. Firstly, in rodents deficient
in leptin or leptin signaling, hyperinsulinemia, and thus the dis-
ruption of normal glucose homeostasis, precedes changes in
body mass (reviewed in Kieffer and Habener, 2000). Secondly,
administration of leptin to ob/ob mice is able to reduce plasma
glucose levels in hours, prior to changes in body weight (Kamo-
hara et al., 1997; Kulkarni et al., 1997; Seufert et al., 1999a).
Thirdly, even when administered for several days, low dosesCELL METABOLISM 4, 291–302, OCTOBER 2006 ª2006 ELSEVIER INCof leptin can virtually cure diabetes in ob/ob mice without alter-
ing body weight (Pelleymounter et al., 1995). Finally, pair feeding
of ob/ob mice cannot correct plasma glucose levels to the same
extent as leptin therapy (Schwartz et al., 1996). Therefore, leptin
appears to have potent actions on glucose homeostasis that are
independent of its effects on food intake and body weight.
The mechanisms by which leptin regulates glucose homeosta-
sis independent of food intake are presently unclear. Studies
with acute intracerebroventricular (ICV) leptin administration
highlight a role for central actions of leptin in the hypothalamus
in manipulating glucose metabolism independent of food intake
and energy balance (Kamohara et al., 1997). Leptin may also reg-
ulate glucose homeostasis through direct actions on insulin-
sensitive peripheral tissues such as liver, adipose, and muscle,
where leptin receptors are found (Ghilardi et al., 1996). Indeed,
leptin has been reported to directly modulate insulin effects in
these tissues (Cohen et al., 1996; Muoio et al., 1997; Siegrist-Kai-
ser et al., 1997). Attenuated leptin receptor expression in adipose
tissue yields hyperinsulinemia and glucose intolerance (Huan
et al., 2003), supporting the notion that direct actions of leptin
on adipose tissue are important for normal glucose homeostasis.
However, genetic ablation of leptin receptors in the liver does
not appear to influence plasma glucose or insulin levels (Cohen
et al., 2001).
Several lines of evidence suggest that insulin-producing pan-
creatic b cells are a direct target of leptin action and thus a
potential mechanism by which leptin can regulate glucose ho-
meostasis. Pancreatic b cells express leptin receptors, including
the long-form ObRb (Emilsson et al., 1997; Ghilardi et al., 1996;
Kieffer et al., 1996; Seufert et al., 1999b), and in vitro studies
indicate that leptin suppresses insulin synthesis and release
(Emilsson et al., 1997; Kieffer et al., 1997; Kulkarni et al., 1997;. DOI 10.1016/j.cmet.2006.09.005 291
A R T I C L EOokuma et al., 1998; Seufert et al., 1999a, 1999b). Leptin ap-
pears to suppress insulin secretion by reducing glucose trans-
port, cellular ATP levels and activating ATP-sensitive K+ chan-
nels leading to cellular hyperpolarization (Harvey et al., 1997;
Kieffer et al., 1997; Lam et al., 2004; Seufert et al., 1999b). As in-
sulin is adipogenic and increases leptin levels (Kolaczynski et al.,
1996; Saladin et al., 1995), feedback inhibition of leptin on insulin
production as part of an ‘‘adipoinsular axis’’ could function as an
endocrine brake to curtail further accumulation of fat (Kieffer and
Habener, 2000).
In this study, we examined the effect of combined disruption
of the leptin receptor gene in pancreatic b cells and hypothala-
mus. We find that this disruption leads to aberrant glucose ho-
meostasis that is a consequence of irregular b cell function.
Importantly, we find that the effects on glucose metabolism
are independent of effects on food intake, thereby supporting
the concept that leptin action on glucose homeostasis and
food intake are independent.
Results
Leprflox/flox RIPcre tg+ mice have tissue-specific
disruption of the leptin receptor gene
To examine the role of leptin in glucose homeostasis, we sought
to generate mice with tissue-specific ablation of leptin receptor
signaling. We made use of Leprflox/flox mice, which have loxP
sites flanking exon 17 of the leptin receptor gene (Lepr) (Baltha-
sar et al., 2004; McMinn et al., 2004). Exon 17 of Lepr is present
in the long, signaling form of the leptin receptor (ObRb) and en-
codes the JAK docking site. Upon Cre-mediated recombination
at the loxP sites, exon 17 is excised (herein referred to as
LeprD17), and a resulting frameshift mutation generates an al-
tered 30 terminus (McMinn et al., 2004) that no longer encodes
tyr985 and tyr1138, which are sites of JAK-mediated tyr phosphor-
ylation. Mice homozygous for the LeprD17 allele are deficient
in leptin-stimulated STAT phosphorylation (Coppari et al.,
2005; Dhillon et al., 2006). The Leprflox/flox mice were crossed
with RIPcre tg+ mice to produce Leprflox heterozygous offspring
that were mated to each other to generate Leprflox/flox and
Leprflox/flox RIPcre tg+ mice. These mice were subsequently
bred to generate animals for experiments. Both male and female
Leprflox/flox RIPcre tg+ mice are fertile, unlike db/db mice. In all
experiments, littermate Leprflox/flox and Leprflox/flox RIPcre tg+
mice were compared to minimize differences in genetic back-
ground. RIPcre tg+ mice have the cre transgene under the con-
trol of a 668 bp segment of the rat insulin II promoter (Postic
et al., 1999). In addition to its well-characterized expression in
pancreatic b cells (Postic et al., 1999), this promoter of the RIP-
cre transgene also leads to low-level Cre expression in neural
derivatives, including the hypothalamus (Gannon et al., 2000).
To characterize the tissue-specific nature of Cre-mediated re-
combination in our Leprflox/flox RIPcre tg+ mice, we harvested
genomic DNA from several tissues that have significant impact
on glucose homeostasis and performed PCR using primers
flanking the loxP sites of the Leprflox allele (Figure 1). PCR of ge-
nomic DNA from adipose, muscle, liver, islet, hypothalamus,
and brain (minus the hypothalamus) tissue from Leprflox/flox
mice with and without theRIPcre transgene resulted in a product
of z1370 bp being amplified. This product corresponded in
size to the predicted size of the product from the Leprflox allele
in the absence of Cre-mediated recombination. In Leprflox/flox292mice carrying the RIPcre transgene, an z 950 bp product was
also amplified in the DNA from islets and weakly amplified in
DNA from hypothalamus tissue. This product corresponds in
size to the expected product from the LeprD17allele. In the islets,
this likely reflects a high degree of excision of the Leprflox allele,
because islets are comprised mainly of b cells but also contain
several noninsulin-producing cells in which Cre is not expressed
(Postic et al., 1999). Thus the Leprflox/flox RIPcre tg+ mice have
a substantial excision of the leptin receptor-signaling domain
in the islets and partial excision in the hypothalamus.
Leprflox/flox RIPcre tg+ mice are obese with reduced
fasting blood glucose
We tracked the body weight and fasting blood glucose of
Leprflox/flox RIPcre tg+ mice and Leprflox/flox littermate controls
from 3–12 weeks of age. In both males and females,
Leprflox/flox RIPcre tg+ mice had a statistically significant in-
crease in body weight (Figures 2A and 2C) relative to controls.
By 6 weeks of age, tissue-specific attenuation of leptin receptor
signaling resulted in a gain ofz13% in males (p = 0.0122) and
18% in females (p = 0.0002). By 12 weeks old, the female
mice with the RIPcre transgene were still z18% heavier than
those without the RIPcre transgene, while in males, the differ-
ence had grown to z33%. The Leprflox/flox RIPcre tg+ mice
tended to be slightly longer in body length, however this differ-
ence was not statistically significant (91.0 6 1.3 mm versus
88.6 6 1.0 mm (p = 0.08) for males and 86.2 6 1.1 mm versus
84.7 6 2.2 mm (p = 0.27) for females for Leprflox/flox RIPcre tg+
and Leprflox/flox, respectively).
In addition to an increase in body weight, tissue-specific at-
tenuation of leptin receptor signaling had an impact on fasting
blood glucose levels (Figures 2B and 2D). At 3 weeks of age,
Leprflox/flox RIPcre tg+ and Leprflox/flox mice had similar fasting
blood glucose levels. However, beyond this point up to 12
weeks old, the Leprflox/flox RIPcre tg+ mice typically had lower
fasting blood glucose. When analyzed by ANOVA pairwise com-
parison, the difference in the average fasting blood glucose from
3–12 weeks of age was statistically significant for males (p =
0.006) and approaching significance in females (p = 0.089).
The extent of the difference in fasting blood glucose was greater
in the males than the females, with an average difference of
Figure 1. RIPcre tg+ results in DNA excision at the Leprflox allele in islets and
hypothalamus
Genomic DNA from tissues of Leprflox/flox mice was used as template for PCR of the
Leprflox allele. The predicted product sizes are 1369 bp for Leprflox and 952 bp for
LeprD17. Arrows to the left mark the migration of molecular weight markers in bp.CELL METABOLISM : OCTOBER 2006
Leptin action on b cells and glucose homeostasisFigure 2. Leprflox/flox RIPcre tg+ mice have increased body weight and fasting hypoglycemia
Leprflox/flox RIPcre tg+ (closed symbols) and Leprflox/flox littermates (open symbols) were fasted for 4 hr, and body weight and blood glucose were measured. Data are ex-
pressed as the average 6 SEM, nR 7. Panels (A) and (C) at each time point p < 0.04 for males and p < 0.02 for females. Panels (B) and (D), p values were determined by
one-way ANOVA pairwise multiple comparison procedure with Holm-Sidak posthoc testing (Sigma Stat, SYSTAT software Inc.) over the 3–12 week period.10.5% 6 2.5% in the males and 5.2% 6 2.1% in the females
over 3–12 weeks of age.
The decreased fasting blood glucose in the Leprflox/flox RIPcre
tg+ mice correlated with increased plasma insulin levels
(Figure 3A). In 6-week-old male Leprflox/flox RIPcre tg+ mice, fast-
ing insulin levels were 5.2-fold higher than Leprflox/flox (p = 0.002).
In females the situation was similar however the increase in in-
sulin in the Leprflox/flox RIPcre tg+ mice was slightly less than
the males at a 4.2-fold increase over the Leprflox/flox mice (p =
0.004). In addition to the elevated plasma insulin levels, there
was also a striking increase in leptin levels in both genders (Fig-
ure 3B). This increase in circulating leptin is consistent with in-
creased adipose mass (Maffei et al., 1995). There was also
a greater than 2-fold increase in plasma triglyceride levels in
the Leprflox/flox RIPcre tg+ mice relative to Leprflox/flox littermates
in both genders (Figure 3C). In contrast, the level of plasma cho-
lesterol was not altered in the Leprflox/flox RIPcre tg+ mice of
either gender (Figure 3D).
The increased body weight and leptin levels of the Leprflox/flox
RIPcre tg+ mice suggested that there might be increased adi-
pose mass in these mice. To investigate this, we performed
magnetic resonance measurements to obtain a ratio of lean/lipid
mass (Figure 3E). The Leprflox/flox RIPcre tg+ mice had a signifi-
cant 2-fold reduction in their lean/lipid composition compared
to controls (p < 0.001). Surprisingly, this difference in body com-CELL METABOLISM : OCTOBER 2006position existed even in mice selected for similar body weight
(24.5 6 3.5 g versus 25.3 6 1.7 g for Leprflox/flox RIPcre tg+
and Leprflox/flox). Magnetic resonance imaging revealed that
there was a massive increase in both visceral and subcutaneous
lipid in Leprflox/flox RIPcre tg+ mice (Figure 3F). This increased
adiposity was particularly striking considering the similar body
weight of the animals imaged (26.4 g versus 25.9 g for the
Leprflox/flox RIPcre tg+ and Leprflox/flox mice, respectively). Nona-
dipose tissue also had an increase in lipid accumulation. He-
patic triglyceride levels were 2.1 6 0.3 and 7.7 6 2.8 mg triglyc-
eride/mg of liver in the Leprflox/flox and Leprflox/flox RIPcre tg+
mice, respectively (n = 4; p = 0.045).
Energy expenditure but not food intake is altered
in Leprflox/flox RIPcre tg+ mice
Since Leprflox/flox RIPcre tg+ mice may have attenuated leptin re-
ceptor signaling in the hypothalamus, we sought to investigate
if leptin-sensitive markers of neuroendocrine function are altered
in Leprflox/flox RIPcre tg+ mice. The circulating levels of corticoste-
rone were increased in Leprflox/flox RIPcre tg+ mice, while ACTH,
testosterone, and thyroxine were not significantly different rela-
tive to controls (Table S1 in the Supplemental Data available
with this article online). Given the normal ACTH levels, the ele-
vated corticosterone could result from direct effects of the hyper-
leptinemia in Leprflox/flox RIPcre tg+ mice on the adrenal cortex.293
A R T I C L EFigure 3. Leprfloxflox/flox RIPcre tg+ have elevated plasma insulin and leptin levels and have a decreased lean/lipid body composition
A–D) Plasma was collected from 4 hr fasted 6-week-old Leprflox/flox RIPcre tg+ mice (filled bars) and Leprflox/flox littermate controls (open bars), n = 3.
E) Total body lean/lipid ratio in 5-week-old Leprflox/flox RIPcre tg+ mice (filled bars) and Leprflox/flox littermate controls (open bars), n = 4.
F) MRI of 6-week-old mice.
In panels (A)–(E), data are expressed as the average 6 SEM.Since leptin is a potent regulator of food intake (Pelleymounter
et al., 1995) and the hypothalamus appears to play a major role
in this effect, we investigated if the increased body weight of
these mice relative to their non-RIPcre transgenic littermates
was a result of increased food intake. We monitored food intake
in 5-week-old Leprflox/flox RIPcre tg+ mice and Leprflox/flox con-
trols over 5 days (Figure 4A). Food intake was comparable be-
tween the groups in both males and females, and differences
were not statistically significant in either gender, a finding that
was also made with 9-week-old mice (data not shown). By294comparison, food intake in 5-week-old db/db mice was signifi-
cantly greater relative to the Leprflox/flox mice either with or with-
out the RIPcre transgene (p < 0.003 in males and p < 0.004 in
females). Thus, food intake does not appear to be altered in
the Leprflox/flox RIPcre tg+ mice, although it remains possible
that differences are present at ages that were not investigated.
The fact that the Leprflox/flox RIPcre tg+ mice do not have in-
creased food intake suggests that the leptin signaling pathways
in the hypothalamus controlling feeding remain functional. To
further test this notion, we treated db/db, Leprflox/flox RIPcre tg+,CELL METABOLISM : OCTOBER 2006
Leptin action on b cells and glucose homeostasisFigure 4. Leprflox/flox RIPcre tg+ mice do not have altered food intake but have decreased energy expenditure
A) Food intake in 5-week-old mice, Leprflox/flox RIPcre tg+ (filled bars), Leprflox/flox (open bars), db/db (gray bars). Males nR 4, females nR 3.
B) Food intake in males following 2 days of leptin treatment (twice daily at 10 mg/g body weight) or vehicle (PBS), nR3.
C) Energy expenditure in 10-week-old male Leprflox/flox RIPcre tg+ (filled bars) or Leprflox/flox (open bars) that were infused with either saline or leptin (2 mg/g body weight per
24 hr), n = 3 for each group. The starting body weights were 27.06 0.9, 27.56 1.2, 32.76 2.5, and 32.26 1.1g for Leprflox/flox (saline and leptin) and Leprflox/flox RIPcre tg+
(saline and leptin), respectively.
D) Cold tolerance of male 12-week-old Leprflox/flox RIPcre tg+ (filled symbols), Leprflox/flox (open symbols), each n = 4 and 29-week-old ob/ob (gray symbols) n = 3.
For all panels, data are expressed as the average 6 SEM.and Leprflox/flox mice with leptin and monitored the effect on
food intake (Figure 4B). Leptin treatment resulted in a substantial
decrease in food intake in both the Leprflox/flox RIPcre tg+ and
Leprflox/flox mice. Although the magnitude of leptin’s anorexic
effect was slightly larger in the non-RIPcre transgenic mice,
this difference was not statistically significant (p = 0.125). As ex-
pected, leptin treatment did not evoke a significant decrease in
food intake in the db/db mice. Collectively these results signify
that leptin action with respect to feeding is not altered in the
Leprflox/flox RIPcre tg+ mice.
Differences in body weight in the absence of altered food
intake could arise as a consequence of decreased energy
expenditure. To explore the possibility that Leprflox/flox RIPcre
tg+ mice might have reduced energy expenditure, we measured
the change in body weight following a 12 hr fast (Figure 4C). At
10 weeks of age, the magnitude of weight loss over the 12 hrCELL METABOLISM : OCTOBER 2006fasting period in Leprflox/flox RIPcre tg+ mice was only 57%
that of the Leprflox/flox controls (p < 0.005). Similar results were
obtained in both genders of 6-week-old mice (p < 0.005, data
not shown). The decreased weight loss of the Leprflox/flox RIPcre
tg+ mice reveals that these mice have decreased energy expen-
diture. Interestingly, leptin treatment was able to normalize
energy expenditure in the Leprflox/flox RIPcre tg+ mice to the level
of the Leprflox/flox mice. The absence of increased energy
expenditure in the controls given exogenous leptin is consistent
with previous studies (Hwa et al., 1997). Thus, despite a reduced
energy expenditure, the data clearly reveal that leptin-sensitive
central pathways controlling energy expenditure in the
Leprflox/flox RIPcre tg+ mice are still intact and functional. Fur-
thermore, unlike ob/ob mice, the Leprflox/flox RIPcre tg+ mice re-
tained normal cold tolerance (Figure 4D). Since thermoregula-
tion appears to be a central leptin-sensitive process (Kowalski295
A R T I C L EFigure 5. Leprflox/flox RIPcre tg+ mice have impaired glucose tolerance and insulin resistance
A–D) OGTT and ITT in 6-week-old Leprflox/flox RIPcre tg+ (closed symbols) and Leprflox/flox littermates (open symbols). Panels (A) and (B), n = 4 Leprflox/flox RIPcre tg+ and
n = 4 Leprflox/flox. Panel (C), n = 5 Leprflox/flox RIPcre tg+ and n = 7 for Leprflox/flox. Panel (D), n = 10 Leprflox/flox RIPcre tg+, and n = 8 Leprflox/flox.
E–F) OGTT in weight-matched male Leprflox/flox RIPcre tg+ (closed bars/symbols) and Leprflox/flox littermates (open bars/symbols) at 12–14 weeks old, n = 5 Leprflox/flox
RIPcre tg+ and n = 4 for Leprflox/flox.
For all panels, data are expressed as the average 6 SEM.et al., 2001), this finding provides further support that hypotha-
lamic leptin signaling is intact in the Leprflox/flox RIPcre tg+ mice.
Leprflox/flox RIPcre tg+ mice have disrupted
glucose homeostasis
To evaluate if the tissue-specific attenuation of leptin receptor
signaling impacted how the mice handle a glucose challenge,
we performed oral glucose tolerance tests (OGTTs) on 6-296week-old Leprflox/flox RIPcre tg+ and Leprflox/flox controls (Figures
5A and 5C). In both genders, the Leprflox/flox RIPcre tg+ mice
showed a prominent impairment in their ability to clear and nor-
malize blood glucose relative to the Leprflox/flox mice. This differ-
ence was statistically significant in both genders but was partic-
ularly striking in the males, with all time points measured from
10–90 min following gavage being significantly different (p <
0.02). The increase in blood glucose of the Leprflox/flox RIPcreCELL METABOLISM : OCTOBER 2006
Leptin action on b cells and glucose homeostasisFigure 6. Leprflox/flox RIPcre tg+ mice have increased islet density and size
Pancreata from 6-week-old female Leprflox/flox RIPcre tg+ (filled bars) and Leprflox/flox littermates (open bars) were sectioned and stained for insulin and glucagon.
A) Islet density expressed as the average number of islets per 1 3 107 mm2 of pancreas area.
B) Islet size expressed as the average 2-dimensional islet size.
C) Total insulin-positive area expressed as the percent of total pancreas area.
D) Size distribution of islets expressed as the percentage of total islets.
E) Images of representative islets from Leprflox/flox RIPcre tg+ and Leprflox/flox mice, green is anti-insulin, red is anti-glucagon, and blue is DAPI. The scale bar represents
25 mm.
For panels (A)–(D), data are expressed as the average 6 SEM, n = 3 for Leprflox/flox RIPcre tg+ and n = 3 for Leprflox/flox.tg+ mice relative to the controls over the 2 hr (determined by area
under the curve) was 1.7-fold (p = 0.018) for males and 1.2-fold
(p = 0.042) for the females. To determine if glucose intolerance in
the Leprflox/flox RIPcre tg+ mice is simply a consequence of in-
creased body mass, we performed OGTTs in weight-matched
Leprflox/flox RIPcre tg+ and Leprflox/flox mice (Figures 5E and
5F). Even in weight-matched animals, the Leprflox/flox RIPcre
tg+ mice were less glucose tolerant than the Leprflox/flox litter-
mates (2281 6 337 versus 1651 6 87 by area under curve
analysis for Leprflox/flox RIPcre tg+ and Leprflox/flox mice, respec-
tively, p = 0.075). This indicates that the glucose intolerance of
Leprflox/flox RIPcre tg+ mice is at least partially independent of
altered body weight.
Recently it has been reported that the RIPcre transgenic line
we employed in this study may be glucose intolerant (Lee
et al., 2006). To investigate this possibility in our mice, we mea-
sured OGT in Leprflox/wt RIPcre tg+ and littermate Leprflox/wt
RIPcre tg- mice (Figures S1A and S1B). In both genders,
we found that glucose tolerance was not disrupted in the
Leprflox/wt mice by the presence of the RIPcre transgene. Thus
the glucose intolerance we observe in the Leprflox/flox RIPcreCELL METABOLISM : OCTOBER 2006tg+ mice is due to the Cre-mediated loss of leptin signaling
and not the transgene itself.
Since the tissue-specific attenuation of leptin receptor signal-
ing resulted in impaired glucose tolerance, we sought to deter-
mine if these mice displayed insulin resistance relative to
controls. Following a 4 hr fast, insulin tolerance tests were
performed on mice 6-8 weeks of age (Figures 5B and 5D). As ex-
pected, both male and female Leprflox/flox controls responded to
insulin with decreases in blood glucose; however the Leprflox/flox
RIPcre tg+ mice had a blunted response to the exogenous
insulin. This difference was statistically significant in both
genders, yet the female Leprflox/flox RIPcre tg+ mice appeared
to be more insulin resistant than their male counterparts.
Attenuated leptin receptor signaling results
in an increase in islet area
Since the Leprflox/flox RIPcre tg+ mice were hyperinsulinemic, we
examined if this corresponded to an increase in islet mass (Fig-
ure 6). In the pancreas of 6-week-old Leprflox/flox RIPcre tg+
mice, there was a statistically significant 46% increase in the
density of islets (p = 0.031). In addition to there being more islets,297
A R T I C L EFigure 7. Glucose-stimulated insulin secretion is impaired in Leprflox/flox RIPcre tg+ mice
A)Plasma insulin levels in 14- to 15-week-old weight-matched male Leprflox/flox RIPcre tg+ (closed symbols, n = 4) and Leprflox/flox littermates (open symbols, n = 3) following
a glucose gavage.
B) Insulin secretion from perifused islets of 6-week-old male Leprflox/flox RIPcre tg+ mice (closed symbols, n = 3) and Leprflox/flox littermates (open symbols, n = 3). Basal
glucose levels are 3 mM.
C) Immunofluorescent images of representative islets from Leprflox/flox RIPcre tg+ and Leprflox/flox mice, where green is anti-insulin, red is anti-GLUT2, and the scale bar
represents a distance of 15 mm.
D) OGTT of male Leprflox/flox RIPcre tg+ (closed symbols) and Leprflox/flox littermates (open symbols) fed either a high-fat diet (circles, nR 8 for both genotypes) starting at 5
weeks old for 10 weeks or a chow diet (squares, n = 4 for both genotypes) for an equivalent time.
For panels (A), (B), and (D), data are expressed as the average 6 SEM.the average size of the islets was increased by z2-fold in the
Leprflox/flox RIPcre tg+ mice, but this did not quite reach statisti-
cal significance. Collectively, the increase in islet number and is-
let size led to a substantial 2.9-fold increase in the islet area
(p = 0.003) in mice with tissue-specific attenuation of leptin
receptor signaling. The lack of leptin receptor signaling did not
appear to alter the overall architecture of the islets as assessed
by immunofluorescence (Figure 6E). In addition, somatostatin
immunoreactivity was not altered by attenuation of leptin recep-
tor signaling (data not shown).
Leprflox/flox RIPcre tg+ mice have defective
glucose-stimulated insulin secretion
To investigate if the loss of glycemic control in the Leprflox/flox
RIPcre tg+ mice is a consequence of insufficient plasma insulin
in response to a glucose challenge, we measured plasma insulin
levels in mice following a glucose gavage (Figure 7A). As ex-
pected, in control Leprflox/flox mice there was a 2.3-fold increase298in plasma insulin shortly after the gavage (p = 0.098). However,
in Leprflox/flox RIPcre tg+ mice we were unable to detect an in-
crease in plasma insulin in response to the glucose. To deter-
mine if this may be a consequence of defective glucose-stimu-
lated insulin secretion from pancreatic b cells, we compared
insulin release from perifused islets from Leprflox/flox RIPcre tg+
and Leprflox/flox mice (Figure 7B). At basal glucose levels, there
was low-level insulin secretion, with Leprflox/flox RIPcre tg+ islets
secretingz1.4 fold more insulin (p < 0.001 by ANOVA pairwise
comparison) than islets from Leprflox/flox mice. However, in re-
sponse to high glucose, relative to controls, there was 47%
less insulin secretion (by area under curve analysis, p = 0.019)
from the Leprflox/flox RIPcre tg+ islets. Despite the decreased glu-
cose-stimulated insulin secretion, islets from Leprflox/flox RIPcre
tg+ mice were equally responsive in insulin secretion to depolar-
ization with 30 mM KCl as islets from Leprflox/flox mice, thereby
indicating that the impaired glucose-stimulated insulin secretion
is not due to a general defect in insulin release.CELL METABOLISM : OCTOBER 2006
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lated insulin secretion in the Leprflox/flox RIPcre tg+ could be an
impaired ability to properly sense glucose. To investigate this
we examined GLUT2 expression in pancreatic b cells of
Leprflox/flox RIPcre tg+ and Leprflox/flox mice (Figure 7C). As ex-
pected, in Leprflox/flox mice, there was abundant peripheral stain-
ing for GLUT2 in the b cells, however, the GLUT2 immunoreac-
tivity was dramatically reduced in the Leprflox/flox RIPcre tg+ mice
(Figure 7C).
Decreased GLUT2 expression and impaired glucose-stimu-
lated insulin secretion can be associated with increased plasma
lipid (Lee et al., 1994) and in fact may arise as a consequence of
excessive lipid (Reimer and Ahren, 2002; Zhou and Grill, 1994).
We sought to investigate how a high-fat feeding regime would
impact the glucose tolerance in Leprflox/flox RIPcre tg+ mice.
Following 10 weeks on a high-fat diet (HFD), glucose tolerance
was measured in Leprflox/flox RIPcre tg+ and Leprflox/floxmice (Fig-
ure 7D). As anticipated, relative to a chow diet, Leprflox/flox mice
fed a HFD were significantly less glucose tolerant (1596 6 131
versus 2059 6 103 by area under curve analysis for chow and
HFD, respectively, p = 0.014). In contrast, relative to a chow
diet, feeding Leprflox/flox RIPcre tg+ mice a HFD had no impact
on glucose tolerance (2648 6 404 versus 2578 6 246 by area
under curve analysis for chow and HFD respectively, p = 0.440).
Discussion
Using a Cre-LoxP recombination approach, we have generated
mice in which the signaling domain of the leptin receptor gene is
disrupted substantially in the pancreatic b cells and partially in
the hypothalamus. This tissue-specific leptin receptor disruption
results in mice with increased body weight, decreased lean/lipid
mass, decreased energy expenditure, insulin resistance, in-
creased islet area, impaired islet function, and glucose intoler-
ance. Notably, the abnormalities in glucose homeostasis in these
mice cannot be entirely accounted for by excessive food intake
and obesity. Instead, the disrupted glucose homeostasis (in
both the fed and fasting state) is a result of b cell malfunction.
A key distinction of the Leprflox/flox RIPcre tg+ mice from other
models of deficient leptin receptor signaling is the reduced fast-
ing blood glucose level. Mice in which leptin receptor signaling is
impaired in POMC neurons (Balthasar et al., 2004), SF1 neurons
(unpublished data) or synapsin I neurons (Cohen et al., 2001)
within the brain have a similar degree of obesity as the
Leprflox/flox RIPcre tg+ mice, but do not have reduced blood glu-
cose levels. Moreover, absent leptin action throughout the body
(ob/ob and db/db) results in obesity, insulin resistance, hyperin-
sulinemia, and hyperglycemia. In striking contrast to this, the
Leprflox/flox RIPcre tg+ mice display chronic reduced fasting
blood glucose. This provides evidence that leptin has effects
on glucose homeostasis that are independent of the regulation
of body weight.
The fasting hypoglycemia following attenuation of leptin re-
ceptor signaling in Leprflox/flox RIPcre tg+ mice likely arises as a
consequence of elevated basal insulin output from the b cells.
This is consistent with the differences we observe between gen-
ders, as the extent of the decreased blood glucose level in the
Leprflox/flox RIPcre tg+ mice is greater in males than females,
as is the hyperinsulinemia. Clearly the elevated basal plasma in-
sulin level in the Leprflox/flox RIPcre tg+ mice is inappropriately
high, as it results in excessively reduced glycemia relative toCELL METABOLISM : OCTOBER 2006the nontransgenic littermate controls. While obesity-induced
insulin resistance may contribute to the hyperinsulinemia, it is
unlikely the primary cause in the Leprflox/flox RIPcre tg+ mice as
such a mechanism would not be expected to overcompensate
to the degree that reduced glycemia is maintained for several
months. Moreover, previous documentation of the acute in-
crease in blood glucose concomitant with decreased insulin
levels within minutes of leptin injection into mice (Kulkarni
et al., 1997) indicates that leptin regulation of insulin release is
not secondary to improvements in insulin sensitivity. These find-
ings support the notion that leptin normally functions to sup-
press insulin secretion, and in its absence, hyperinsulinemia
ensues (Kieffer and Habener, 2000; Seufert, 2004).
A fundamental issue in the field regarding leptin action on glu-
cose homeostasis is the relevant contribution of leptin at central
versus peripheral sites. With the Leprflox/flox RIPcre tg+ mice, we
cannot unambiguously attribute the disrupted glucose homeo-
stasis specifically to central or peripheral pathways, but our re-
sults provide some insights. The fasting hypoglycemia that we
observe arises as a consequence of increased insulin output
from b cells. Consistent with this being a b cell autonomous re-
sponse, we observed such increases in insulin secretion in the
basal state in isolated islets. It is conceivable that a hypothalamic
leptin signaling pathway may alter insulin secretion from b cells,
persisting even after islets are removed from central control.
However, other central leptin signaling pathways controlling
food intake and energy expenditure are not severed in the
Leprflox/flox RIPcre tg+ mice as they still responded acutely to ex-
ogenous leptin. Furthermore, although leptin regulated central
pathways controlling insulin secretion are plausible, ICV admin-
istration of leptin does not appear to acutely alter plasma insulin
levels (Kamohara et al., 1997), while peripheral administration
does (Kulkarni et al., 1997; Seufert et al., 1999a). The hypothesis
that loss of direct leptin signaling at b cells leads to basal hyper-
insulinemia and fasting hypoglycemia is consistent with numer-
ous studies showing leptin can inhibit insulin secretion from iso-
lated islets (Emilsson et al., 1997; Kieffer et al., 1997; Kulkarni
et al., 1997; Ookuma et al., 1998; Seufert et al., 1999a, 1999b).
Thus, the fasting hyperinsulinemia and reduced fasting blood
glucose in Leprflox/flox RIPcre tg+ mice appear to be more consis-
tent with peripheral rather than central actions of leptin.
Despite a near 3-fold increase in islet area, Leprflox/flox RIPcre
tg+ mice display striking hyperglycemia following a glucose
load. Glucose intolerance in the presence of increased b cell
mass is also observed in rodents with mutations in the leptin
receptor gene (db/db mice and ZDF rats). Although the glucose
intolerance is partially attributable to insulin resistance in
Leprflox/flox RIPcre tg+, it is not likely the primary reason. Female
Leprflox/flox RIPcre tg+ mice handled the glucose load better than
the male Leprflox/flox RIPcre tg+ mice, despite having greater re-
sistance to insulin. Following a glucose challenge, we were un-
able to detect a surge in plasma insulin in Leprflox/flox RIPcre tg+
mice leading us to speculate that glucose-stimulated insulin se-
cretion was impaired. Perifusion studies with islets isolated from
Leprflox/flox RIPcre tg+ mice confirmed that these mice had atten-
uated glucose-stimulated insulin secretion relative to controls.
Therefore, decreased glucose-dependent insulin secretion
from b cells is probably the primary mechanism contributing to
the glucose intolerance of the Leprflox/flox RIPcre tg+ mice.
Interestingly, while insulin secretion from islets isolated from
Leprflox/flox RIPcre tg+ mice was impaired in response to299
A R T I C L Eglucose, it was normal following depolarization with KCl. Thus
the defect that results from chronically absent leptin signaling
does not restrict the readily releasable pool of insulin. A potential
mechanism of impaired glucose-stimulated insulin secretion is
reduced GLUT2 expression in b cells as a consequence of ex-
cessive lipid, an observation made in db/db mice and ZDF
rats. Leptin has been proposed to protect nonadipose tissue
from excessive triglyceride accumulation and lipotoxicity (Un-
ger, 2002). Moreover, excessive lipid accumulation in b cells re-
sults in decreased GLUT2 and impairment of glucose-stimu-
lated insulin secretion (Lee et al., 1994; Wang et al., 1998).
Thus, it is possible that the loss of leptin receptor signaling in
b cells leads to excessive triglyceride accumulation, which sec-
ondarily impairs glucose-stimulated insulin secretion. Such
a scenario is compatible with our finding that additional expo-
sure to lipid via maintenance on a HFD could not further impair
glucose homeostasis in the Leprflox/flox RIPcre tg+ mice.
In addition to the elevated plasma lipid levels, the Leprflox/flox
RIPcre tg+ mice have a striking increase in lipid mass and a de-
crease in lean mass. Moreover, the increased lipid to lean mass
of the Leprflox/flox RIPcre tg+ can occur in the absence of differ-
ences in total body weight. Thus the altered body composition is
not strictly additional fat mass, as is observed in mice with atten-
uated leptin signaling in POMC and SF1-positive neurons (Dhil-
lon et al., 2006). Such a change in body composition in the ab-
sence of increased body mass does not seem likely to arise as
a consequence of the altered energy expenditure. Rather the al-
tered composition suggests that these mice either have a pro-
pensity for adipogenesis or a preferential utilization of carbohy-
drates over lipids. Such changes are consistent with the actions
of insulin, and thus may arise as a consequence of fasting hyper-
insulinemia in the Leprflox/flox RIPcre tg+ mice. While hyperlepti-
nemia may be expected to decrease ectopic lipid accumulation
in tissues with functional leptin receptors such as liver (Unger,
2002), this appears to be overcome by the actions of insulin
and elevated plasma triglycerides in this model.
In summary, our studies indicate that leptin has important ac-
tions on glucose homeostasis that are independent of the path-
ways by which leptin regulates food intake and body weight.
Leptin appears to be important in restraining insulin secretion
such that attenuated leptin action can cause hyperinsulinemia.
As suggested by Coleman during early characterization of the
ob/ob and db/db phenotypes (Coleman, 1978), it is quite con-
ceivable that excessive insulin release could alone account for
weight gain, insulin resistance, and fasting hypoglycemia.
Thus leptin resistance leading to hyperinsulinemia may provide
another mechanism by which obesity can contribute to diabe-
tes. Furthermore, this hypothesis also provides a potential
mechanism by which leptin resistance could lead to diabetes
independent of the development of obesity. Indeed, Raskin
and colleagues suggested that dysregulation of the adipoinsular
axis could explain the obesity-independent hyperinsulinemia
they observed in nondiabetic first-degree relatives of individuals
with type 2 diabetes (Ishikawa et al., 1998). These hypotheses
warrant further investigation.
Experimental procedures
Mice
C57BL/6-TgN(RIPcre)25Mgn (referred to as RIPcre tg+) were obtained from
The Jackson Laboratory (Bar Harbor, ME). Mice were housed with a 12 hr300light/12 hr dark cycle and had ad libitum access to food (chow diet: 5015
Lab Diet, St Louis, MO, or high-fat diet when specified: #D12330, Research
Diets, New Brunswick, NJ) and water. All procedures with animals were ap-
proved by the University of British Columbia Animal Care Committee and car-
ried out in accordance with the Canadian Council on Animal Care guidelines.
C57Bl6/JRIPcre tg+ mice were mated with Leprflox/flox (129 X FVB N6) to gen-
erate Leprflox/wt either with or without the RIPcre transgene. These offspring
(z50% C57Bl6/J, 50% FVB, and less than 1% 129) were bred, with one
mouse of each pair harboring the RIPcre tg+. The offspring that were
Leprflox/flox RIPcre tg+ and Leprflox/flox RIPcre tg- (referred to as Leprflox/flox)
were mated to produce Leprflox/flox RIPcre tg+ mice and Leprflox/flox littermate
controls for experiments. For all experiments, littermate Leprflox/flox controls
were compared with Leprflox/flox RIPcre tg+ mice in order to minimize differ-
ences in genetic background, which can affect the phenotype of leptin
deficiency (Haluzik et al., 2004).
Plasma analyte analysis
Body weight and blood glucose were measured following a 4 hr fast. Blood
glucose was measured with a One Touch Ultra Glucometer (Life Scan Inc.,
Burnaby, Canada) from the saphenous vein and leptin (mouse leptin ELISA,
LINCO Research, St. Charles, MO), insulin (Ultrasensitive Mouse Insulin
ELISA, Mercodia, Uppsala, Sweden), triglyceride (Serum Triglyceride kit,
Sigma-Aldrich, St Louis, MO) and cholesterol (Cholesterol E kit, Wako
Chemical, Richmond, VA) from plasma.
Analysis of ACTH, corticosterone, testosterone and total thyroxine
Blood samples were collected from 13- to 15-week-old fed Leprflox/flox RIPcre
tg+ and Leprflox/flox mice between 10 AM and 11 AM, either by the saphenous
vein for the preparation of plasma or by cardiac puncture under isoflurane an-
esthesia for the preparation of serum. Levels of corticosterone (EIA kit from
Assay Designs, Ann Arbor, MI), total thyroxine (RIA kit from Diagnostic Prod-
ucts Corporation, Los Angeles, CA), and testosterone (EIA kit from MP Bio-
medicals, Orangeburg, NY) were measured in serum. Levels of ACTH (RIA
kit from Diagnostic Systems Laboratories, Inc., Webster, TX) were measured
in plasma.
Islet isolation
Islets were isolated using the method described by Salvalaggio et al. (2002).
PCR analysis
Genomic DNA was prepared with DNeasy kits (Qiagen, Mississauga, Can-
ada). Brain tissue was prepared as a homogenate of the brain minus the hy-
pothalamus. For PCR reactions, 3 ml of genomic DNA was added to a 25 ml
reaction containing 13PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 1 U/ml Plat-
inum Taq DNA polymerase (all from Invitrogen, Burlington, Canada), and
1 mM of each forward and reverse primer (Integrated DNA Technologies
Inc., Coralville, IA). For Leprflox PCR reactions the forward primer was ATG
CTA TCG ACA AGC AGC AGA ATG ACG and the reverse primer CAG GCT
TGA GAA CAT GAA CAC AAC AAC. PCR for the presence of the RIPcre
transgene was performed with forward primer AAT GGG ACA AAC AGC
AAA GTC C and reverse primer AGA TAA TCG CGA ACA TCT TCA GGT.
In vivo glucose-stimulated insulin secretion, oral glucose tolerance,
and insulin tolerance tests
Mice were fasted for 4 hr and then either given an oral gavage of 1.5 mg/g
body weight glucose as a 25% solution or an intraperitoneal injection of
0.4 U/kg human synthetic insulin (Novo Nordisk Canada Inc, Mississauga,
Canada).
Islet morphology
Mice were given a 600 ml intraperitoneal injection of 2.5% avertin (Sigma-
Aldrich, St Louis, MO), and pancreata were removed. Pancreata were fixed
in 4% paraformaldehyde overnight at 4C, rinsed in 70% ethanol, embedded
in paraffin, and 3 mm sections were prepared. Sections were stained with
guinea pig anti-insulin (LINCO Research, St. Charles, MO) and mouse anti-
glucagon (Sigma-Aldrich, St Louis, MO) overnight at 4C and then with
goat anti-guinea pig Alexa Fluor 488 and donkey anti-mouse Alexa Fluor
594 (Molecular Probes, Eugene, OR). For morphometric analysis, three ran-
domly chosen fields of 0.26 cm2 were measured for pancreas area as well as
insulin-positive area using Openlab Software (Improvision, Lexington, MA).CELL METABOLISM : OCTOBER 2006
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the investigator blind to the genotype. For GLUT2 staining, pancreata (pre-
pared as described above) were stained with rabbit anti-GLUT2 (Chemicon
International Inc, Temecula, CA) overnight at 4C and then with donkey
anti-rabbit Alexa Fluor 594.
Islet perifusion analysis
Islets were cultured overnight, and then 100 islets from each mouse were
loaded into separate chambers of an Acusyst-S perifusion apparatus (Endo-
tronics Cell Culture Instrumentation, Minneapolis, MN) with Cytodex micro-
carrier beads (Sigma-Aldrich, St Louis, MO). Islets were equilibrated in cham-
bers with pH 7.2 KRBB containing 0.5% BSA and 3 mM glucose for 45 min
at a flow rate of 0.36 ml/min. At the indicated times, the concentration of
glucose and KCl were altered.
Food intake studies
Mice were housed individually in cages with wire grid inserts on the cage
floor. Mice were acclimatized to the cages for 2 days after which food intake
(the difference in weight of food in the hopper and that remaining in hopper
and on the floor 24 hr later) was measured for 5 days and averaged.
Assessment of energy expenditure
At the end of the dark cycle, osmotic pumps (2001D, Durect Corporation,
Cupertino, CA) delivering either saline or 2 mg leptin/g body weight were
implanted subcutaneously in mice. Mice were weighed and food was with-
drawn for 12 hr, and then mice were weighed again.
Cold tolerance
Microchips (Bio Medic Data Systems) were implanted subcutaneously into
mice that were housed individually in cages without bedding. Mice were
placed in a 4C environment, and body temperature was measured every
30 min for 2 hr using a Pocket Scanner (Bio Medic Data Systems).
Magnetic resonance imaging
Mice were euthanized and imaged in a Bruker Biospec 70/30 7 Tesla MRI
Scanner (Bruker Biospin, Ettlingen, Germany). Images were acquired in the
abdominal region in 1 mm axial slices with MSME T1-weighted pulse se-
quence, with and without fat suppression. Pseudocolored lipid images
were obtained by subtracting images collected with fat suppression from
images acquired without fat suppression.
Measurement of lean to lipid mass
Measurements were performed with a Bruker Biospec 70/30 7 Tesla MRI
scanner (Bruker Biospin, Ettlingen, Germany). NMR signal from the body
was acquired with a quadrature volume RF coil tuned to 300 MHz. The
‘‘free’’ water component corresponding to body fluids, e.g., urine and CSF,
was typically less than 5% of the total signal. The ratio of lean/fat tissue is
expressed as weight/weight was calculated from the NMR data as described
in (Kunnecke et al., 2004).
Measurement of tissue triglycerides
Triglyceride was measured by a modified protocol (Briaud et al., 2001). Liver
was homogenized with an ultra turrax in 3 ml of chloroform:methanol (2:1),
and extracted twice with water. 1 ml of the organic layer was dried by N2(g)
and 20 ml of Thesit (Sigma-Aldrich) was added and mixed under N2(g). Water
(100 ml) was added and incubated at 37C for 30 min with intermittent vortex-
ing. Aliquots (2 and 20 ml) were assayed using the Serum Triglyceride Deter-
mination kit (Sigma-Aldrich) modified for a 96-well plate, calibrated with a
trioleate (Sigma-Aldrich) standard curve.
Supplemental data
Supplemental data include one figure and one table and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/4/4/
291/DC1/.
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